OncoMed Pharmaceuticals, Inc. Company Profile
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed's lead candidate, OMP-21M18, is currently in Phase I clinical trials. In addition to OMP-21M18, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. Privately-held, OncoMed's investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the company's website: www.oncomed.com.
News Articles
Lonza to develop OncoMed anti-cancer therapeutics
Lonza has signed an agreement with OncoMed to develop and manufacture OncoMed's pipeline of anti-cancer stem cell therapeutics.
OncoMed contracts Lonza to manufacture cancer drugs
Lonza will develop and manufacture OncoMed's pipeline of experimental stem cell treatments for cancer. -More-
OncoMed Pharmaceuticals initiates PI Trial of Anti-Cancer Stem Cell Therapeutic
Cell Therapeutic OMP-54F28 (Fzd8-Fc) OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells has beg...
FDA Clears OncoMed's Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US
Partial Clinical Hold Removed By FDA REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 2, 2013 - OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells...
Martinsried - Der Biotechnologiekonzern MorphoSys AG (ISIN DE0006632003/ WKN 663200) gab am Freitag bekannt, dass sein Kooperationspartner OncoMed Pharmaceuticals den HuCAL-Antikörper OMP-59R5 in d.....
OncoMed highlights progress of anti-cancer biologics at AACR annual meeting
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progre...
OncoMed commences OMP-59R5 Phase 1b/2 small cell lung cancer trial
OncoMed Pharmaceuticals has commenced Phase 1b/2 trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer (SCLC) patients.
MorphoSys AG / MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and...
OncoMed Pharmaceuticals is pioneering the development of novel therapeutics that target a new class of solid tumor cells, known as "cancer stem cells". The company's technology is based on a recent di...
Morgenthaler Ventures is a premier venture capital firm, dedicated to helping entrepreneurs build valuable companies for more than 40 years. Today, the firm has nearly $3 billion under management, inc...
More Information about "OncoMed Pharmaceuticals, Inc." on BioPortfolio
We have published hundreds of OncoMed Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of OncoMed Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about OncoMed Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OncoMed Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant OncoMed Pharmaceuticals, Inc. Drugs and Medications on this site too.
